BWX Technologies, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BWXT research report →
Range $170 – $245
Price Chart
About the company
BWX Technologies, Inc. operates globally, specializing in the production and sale of nuclear components across the United States, Canada, and other international regions. The company's multifaceted operations are categorized into three distinct segments: Nuclear Operations Group, Nuclear Power Group, and Nuclear Services Group.
- CEO
- Rex D. Geveden
- IPO
- 2010
- Employees
- 10,400
- HQ
- Lynchburg, VA, US
AI snapshot
Six angles, distilled from the data.
The stock remains in a deep corrective regime, trading well below its 200-day average and far under its 52-week high. The setup is still rebuilding after a long drawdown, with the share price now much closer to the yearly low than the prior peak.
Street sentiment stays constructive, with a Buy consensus and an average target around 200, implying meaningful upside from current levels. Recent actions have been mixed but still supportive: several firms initiated or reiterated Buy, while target cuts have pulled expectations lower without breaking the broader positive stance.
Execution has been strong, with BWXT beating EPS in all 8 of the last 8 quarters. Next-year EPS is modeled higher at 5.2187 versus 4.07 TTM, so shareholders should watch whether the company keeps converting steady revenue growth into another margin-backed beat.
No notable discretionary insider buying or selling. Recent activity is dominated by award, vesting, and exempt-related transactions for officers and directors, which reads as routine compensation flow rather than a directional signal.
Profitability is solid, with a 22.6% gross margin, 10.42% operating margin, and 10.41% net margin. Growth is steady rather than explosive: revenue rose 10.0% year over year and earnings grew 24.6%, while ROE reached 28.27%.
BWXT stands out as a niche nuclear-defense and commercial nuclear supplier with recurring government exposure and specialized manufacturing. The valuation is not cheap versus the market, at 27.62x earnings, but the premium reflects durable margins and steady cash generation.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $9.94B
- P/E
- 26.54
- Fwd P/E
- 22.82
- PEG
- 1.22
- P/S
- 2.76
- P/B
- 7.02
- EV/EBITDA
- 19.86
- Div Yield
- 1.00%
- Gross Margin
- 22.58%
- Op Margin
- 10.53%
- Net Margin
- 10.41%
- ROE
- 28.48%
- ROIC
- 8.29%
Latest fiscal year · YoY change
- Revenue
- $3.20B+18.3%
- Gross Profit
- $731.52M+11.6%
- Op Income
- $323.24M
- Net Income
- $329.86M+17.0%
- EPS
- $3.60+16.9%
- OCF Growth
- +17.5%
- FCF Growth
- +15.9%
- 52W High
- $241.82
- 52W Low
- $108.17
- 50D MA
- $134.36
- 200D MA
- $178.85
- Beta
- 0.74
- RSI (14)
- 30
- Avg Volume
- 1.27M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
BWXT reported a strong third quarter with 10% revenue growth, 19% Adjusted EBITDA growth, and upbeat 2027/2030 commentary driven by nuclear demand, special materials ramp, and new reactor awards.· November 2, 2026
- Q3 revenue rose to $953 million, up 10% year over year, with 7% organic growth.
- Adjusted EBITDA increased 19% to $180 million and adjusted EPS rose 26% to $1.26.
- Government Operations margin was 22.6%, while Commercial Operations revenue grew 25% and segment EBITDA rose 17%.
- Management raised 2026 free cash flow guidance to $350 million-$360 million and kept 2026 operating guidance unchanged.
- 2027 outlook calls for high single-digit to low double-digit Adjusted EBITDA and EPS growth, with strong support from Special Materials and operational execution.
Third-quarter revenue was $953 million, up 10% year over year, including 7% organic growth. Adjusted EBITDA rose 19% to $180 million, and adjusted EPS increased 26% to $1.26. Third-quarter free cash flow was $151 million. Government Operations revenue increased 4%, with Adjusted EBITDA of $144 million and a 22.6% margin; Commercial Operations revenue increased 25% (15% organic) and Adjusted EBITDA reached $41 million, with a 13.2% margin. For 2026, BWXT left operating guidance unchanged and now expects Adjusted EBITDA of about $667 million and adjusted EPS of $4.72 to $4.77. Management also raised 2026 free cash flow guidance to $350 million-$360 million. For 2027, the company gave preliminary outlook for high single-digit to low double-digit Adjusted EBITDA and EPS growth, Government Operations growth in that same range, Commercial Operations high single-digit organic revenue growth and low single-digit total revenue growth due to a planned medical divestiture, and free cash flow flat to slightly higher versus 2026.
Rex Geveden said the quarter validated the company’s Investor Day framework and argued that BWXT is turning strong nuclear demand into executable programs and sustained financial growth. He highlighted broad momentum across government and commercial nuclear, including special materials ramps, advanced nuclear wins like Janus, BANR and Antares, and capacity additions in Cambridge and planned U.S. manufacturing. His tone was confident and expansive, repeatedly emphasizing that the company is well positioned for the next phase of nuclear growth.
Mike Fitzgerald focused on the numbers and the bridge to next year. He cited $953 million of revenue, $180 million of Adjusted EBITDA, $1.26 of adjusted EPS, and $151 million of free cash flow in Q3, then said 2026 guidance remains intact at about $667 million of Adjusted EBITDA and $4.72 to $4.77 of adjusted EPS, with free cash flow now guided to $350 million-$360 million. He also said capex should be about 6% of revenue in both 2026 and 2027, noted Fitch’s inaugural investment-grade rating and Moody’s positive outlook revision, and described capital allocation as prioritizing organic growth investments, optional acquisitions, and shareholder returns when appropriate.
Analysts pressed on Government Operations margins, and management said the strength came mainly from better execution and efficiency in the naval nuclear business, while newer programs are still early and not yet fully reflected in margins. Questions on PCG focused on the roughly $500 million of backlog and how it will run off; management said the business has been integrated well, most of the backlog is naval work, and the acquired plant still has about 50% unutilized capacity that can be used for commercial work. Analysts also probed commercial order timing, risk allocation for new nuclear builds, and the U.S./Poland heavy-component investment plans; management said order flow is expected to improve by late 2026 or early 2027, and that the main gating issue for large projects is risk-sharing rather than financing.
BWXT is showing strong operating leverage now, with revenue, EBITDA and EPS all growing double digits and margin performance improving in Government Operations. The company also pointed to multiple growth engines—special materials, advanced nuclear, commercial power, and capacity expansions—while saying it is winning real contracts, not just talking about a market opportunity.
Some of the growth story still depends on programs ramping later, including HPDU, enrichment, and commercial new-build awards, so timing remains important. Management also acknowledged pressure points such as margin mix, working-capital investment, pension contributions, and the need for risk-sharing structures before major commercial reactor projects reach FID.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.6%
- Shares Outstanding
- 91.63M
- Float Shares
- 91.24M
of shares held by institutions
887 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for BWXT, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| April McClain DelaneyHouse · MD06 | Buy | Aug 3, 26 | Filing → |
| April McClain DelaneyHouse · MD06 | Sell | Aug 25, 26 | Filing → |
| April McClain DelaneyHouse · MD06 | Buy | Jul 24, 26 | Filing → |
| April McClain DelaneyHouse · MD06 | Buy | Jul 27, 26 | Filing → |
| April McClain DelaneyHouse · MD06 | Buy | Jul 30, 26 | Filing → |
| April McClain DelaneyHouse · MD06 | Buy | May 14, 26 | Filing → |
| April McClain DelaneyHouse · MD06 | Buy | May 7, 26 | Filing → |
| April McClain DelaneyHouse · MD06 | Buy | May 8, 26 | Filing → |
| April McClain DelaneyHouse · MD06 | Buy | May 15, 26 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Oct 30, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Oct 30, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Oct 31, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Jun 11, 25 | Filing → |
| Lois FrankelHouse · FL22 | Sell | Sep 8, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 11.18M | ▼ 941.47K |
| Vanguard Group Inc | 9.01M | ▼ 167.39K |
| Vanguard Portfolio Management LLC | 4.68M | ▼ 75.10K |
| Vanguard Capital Management LLC | 4.13M | ▼ 11.15K |
| State Street Corp | 3.97M | ▲ 173.55K |
| Jpmorgan Chase & Co | 2.36M | ▼ 295.80K |
| First Trust Advisors LP | 2.30M | ▲ 222.96K |
| Alkeon Capital Management LLC | 2.02M | ▲ 283.40K |
| Franklin Templeton Inc | 1.88M | ▼ 46.42K |
| Geode Capital Management, LLC | 1.84M | ▼ 19.67K |
| Van Eck Associates Corp | 1.73M | ▲ 168.51K |
| Select Equity Group, L.P. | 1.70M | ▲ 977.58K |
Held by 522 ETFs
Biggest fund positions in BWXT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 26 | Smith Toby W. | other | 86.05 |
| Nov 16, 26 | Cajade Gonzalo Raul | other | 5.279 |
| Nov 6, 26 | Cajade Gonzalo Raul | other | 124.33 |
| Sep 4, 26 | Burbach Gerhard F | other | 23.19 |
| Sep 4, 26 | JASKA JAMES M | other | 28.29 |
| Sep 4, 26 | JABLONSKY DANIEL L | other | 1.52 |
| Sep 4, 26 | Krieg Kenneth J | other | 36.14 |
| Sep 4, 26 | Melvin Leland D | other | 15.43 |
| Sep 4, 26 | PIASECKI NICOLE WEYERHAEUSER | other | 7.8 |
| Sep 4, 26 | Richardson John M | other | 16.44 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BWXT coverage
Recent articles, reports, and earnings notes.

Ampera SPAC Merger: The Bull and Bear Case
Ampera is going public through a merger with Berto Acquisition Corp. (Nasdaq: TACO), with the deal expected to close in Q1 2027. The bull case is a big AI-power and nuclear optionality story; the bear case is that the company is still early-stage, capital-hungry, and exposed to redemption and dilution risk.

newcleo plc IPO: What Investors Need to Know
newcleo plc Ordinary Shares is expected to list on NASDAQ on 2026-09-22, with the price range not yet disclosed. The deal is being pursued through a SPAC business combination with NewHold Investment Corp III under ticker NWCL. The setup favors investors who want exposure to advanced nuclear and fuel-cycle optionality, but the key watch item is whether the company can convert a long-dated technology story into a credible public-market path.

HGP Intelligent Energy Is Going Public via SPAC — AI Power Upside
HGP Intelligent Energy is a Dallas-based energy and technology developer going public via a merger with Meshflow Acquisition Corp (Nasdaq: MESH). The deal is pitched as an AI/data-center power play, but shareholders should watch the gap between the $800.0 million pre-money valuation and the company’s pre-commercial stage.
Want a deeper read on BWXT?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
BWXT Completes C$80 Million Facility Expansion, Boosting Nuclear ETFs
etftrends.com · Nov 20
Can BWXT's Cambridge Expansion Support Nuclear Reactor Growth?
zacks.com · Nov 19
BWX Technologies: Upgrading To Buy After The Correction
seekingalpha.com · Nov 18
The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
marketbeat.com · Nov 17
Existing Nuclear Fleet Upgrades Drive Investment Momentum
etftrends.com · Nov 16
Access Financial Services Inc. Buys New Stake in BWX Technologies, Inc. $BWXT
defenseworld.net · Nov 15
Dividend Champion, Contender, And Challenger Highlights: Week Of November 15
seekingalpha.com · Nov 13
BWXT Completes Cambridge Facility Expansion, Prepares for Future Nuclear New Build
businesswire.com · Nov 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 19, 2026 · Live quote · Not investment advice